• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Phathom Pharmaceuticals Inc.

    6/9/25 10:47:42 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHAT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    PHATHOM PHARMACEUTICALS INC

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    71722W107

    (CUSIP Number)


    05/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    71722W107


    1Names of Reporting Persons

    Jennison Associates LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PHATHOM PHARMACEUTICALS INC
    (b)Address of issuer's principal executive offices:

    100 Campus Drive, Suite 102, Florham Park, NJ 07932
    Item 2. 
    (a)Name of person filing:

    Jennison Associates LLC
    (b)Address or principal business office or, if none, residence:

    55 East 52nd Street, New York, NY 10055
    (c)Citizenship:

    USA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    71722W107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Jennison Associates LLC
     
    Signature:Beata Markowicz
    Name/Title:Senior Vice President, Compliance
    Date:06/09/2025
    Get the next $PHAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHAT

    DatePrice TargetRatingAnalyst
    2/14/2025$23.00Overweight
    Cantor Fitzgerald
    5/3/2024$24.00Buy
    Stifel
    1/5/2024$23.00 → $26.00Buy
    Needham
    8/9/2023$28.00Buy
    H.C. Wainwright
    5/11/2023In-line → Outperform
    Evercore ISI
    3/13/2023$21.00Buy
    Craig Hallum
    10/21/2022$16.00Buy
    Jefferies
    5/6/2022Outperform → In-line
    Evercore ISI
    More analyst ratings

    $PHAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Phathom Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals with a rating of Overweight and set a new price target of $23.00

      2/14/25 7:06:18 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Phathom Pharmaceuticals with a new price target

      Stifel initiated coverage of Phathom Pharmaceuticals with a rating of Buy and set a new price target of $24.00

      5/3/24 7:37:39 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Phathom Pharmaceuticals with a new price target

      Needham reiterated coverage of Phathom Pharmaceuticals with a rating of Buy and set a new price target of $26.00 from $23.00 previously

      1/5/24 8:05:02 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Topper James N bought $14,609 worth of shares (3,780 units at $3.86) (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/23/25 4:06:35 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $24,462 worth of shares (7,420 units at $3.30) (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/15/25 4:17:38 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $152,917 worth of shares (48,203 units at $3.17) (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/13/25 4:13:04 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Karbe Frank was granted 10,500 shares, increasing direct ownership by 18% to 67,500 units (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      6/5/25 4:58:25 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Cola Michael F was granted 10,500 shares, increasing direct ownership by 36% to 39,798 units (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      6/5/25 4:58:12 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fields Heidi was granted 10,500 shares, increasing direct ownership by 54% to 30,000 units (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      6/5/25 4:56:32 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

      Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

      7/18/24 10:52:01 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

      Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

      5/11/22 10:51:07 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

      Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer

      5/11/22 10:17:03 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care